Bellini duct carcinoma
Gil Falcão; Anuraj Quiran Parmanande; Catarina Araújo; João Vasco Barreira
Abstract
Keywords
References
1 Turajlic S, Swanton C, Boshoff C. Kidney cancer: the next decade. J Exp Med. 2018;215(10):2477-9.
2 Fleming S, Lewi HJ. Collecting duct carcinoma of the kidney. Histopathology. 1986;10(11):1131-41.
3 Tokuda N, Naito S, Matsuzaki O, Nagashima Y, Ozono S, Igarashi T. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol. 2006;176(1):40-3.
4 Mishra AK, Manikandan R, Dorairajan LN, Mittal JK, Rekha JS. Bellini duct carcinoma: a rare entity. J Clin Diagn Res. 2016;10(10):PD01-02.
5 Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20(9):2376-81.
6 Dason S, Allard C, Sheridan-Jonah A, et al. Management of renal collecting duct carcinoma: a systematic review and the McMaster experience. Curr Oncol. 2013;20(3):e223-32.
7 Ahrens M, Scheich S, Hartmann A, Bergmann L. Non-clear cell renal cell carcinoma: pathology and treatment options. Oncol Res Treat. 2019;42(3):128-35.
8 Albadine R, Schultz L, Illei P, et al. PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. Am J Surg Pathol. 2010;34(7):965-9.
Submitted date:
07/10/2020
Accepted date:
08/20/2020
Publication date:
12/08/2020